Lulu Xu joined NEA in 2021 as an investor on the healthcare team. She focuses on later stage life sciences investments.
Before joining NEA, Lulu worked at AbbVie in several roles across R&D and M&A. Most recently she worked in AbbVie's Enterprise Strategy group on the acquisition and integration of Allergan and Pharmacyclics. Prior to that she worked on the data science team leading digital health initiatives and she was part of AbbVie's leadership rotational program.
Lulu attended the Stanford University Graduate School of Business, where she co-founded the life sciences venture program Nucleate Bio Bay Area. She received a BS from Northwestern University in both Neuroscience and Communication Sciences & Disorders.